Prescient advancing new cancer therapies with a leading team of global cancer specialists
To fight the menace of cancer, there have been categorical and highly efficacious progress in...
To fight the menace of cancer, there have been categorical and highly efficacious progress in...
A clinical-stage oncology company, Prescient Therapeutics (ASX:PTX) has further strengthened its Scientific Advisory Board (SAB) with the...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has made plans to advance and accelerate its proprietary...
Biotechnology companies have emerged from the COVID pandemic in “healthy if not robust” shape and...
One of the leading clinical-stage oncology companies, Prescient Therapeutics Limited (ASX:PTX), has been making its...
Prescient Therapeutics Limited (ASX: PTX) has released the results for September quarter of fiscal year...
Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs...
Summary Prescient Therapeutics (ASX:PTX): We spoke with Steve Yatomi-Clarke, CEO of Prescient Therapeutics, about the exciting new...
Prescient Therapeutics (ASX: PTX) CEO Steven Yatomi-Clarke recently presented at the AusBiotech Investment Conference 2021....
Prescient Therapeutics’ next-generation CAR-T platform OmniCAR has delivered overwhelmingly positive results in recent pre-clinical studies...

This investor centre was built by Reach Markets
©2025 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.